Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Novel therapies and pitfalls in MPNs

Abdulraheem Yacoub • 12 Jun 2020
EHA 2020
Myeloproliferative Neoplasms Ruxolitinib

Abdulraheem Yacoub, MD, of the University of Kansas Medical Center, Kansas City, MO, outlines novel therapy approaches and pitfalls in the treatment of myeloproliferative neoplasms (MPNs). Dr Yacoub explores the use of JAK inhibitors for this indication as well as ongoing clinical trials investigating combination therapies for MPNs. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Abdulraheem Yacoub

2:06
Parsaclisib plus ruxolitinib in myelofibrosis: a promising strategy for treatment-naive patients
Abdulraheem Yacoub • 26 Aug 2022
2:42
The management of advanced phase MPNs
Abdulraheem Yacoub • 26 Aug 2022
4:15
The latest data on momelotinib for MPNs
Abdulraheem Yacoub • 10 Aug 2021
4:11
Novel therapies and combinations for myelofibrosis patients
Abdulraheem Yacoub • 10 Aug 2021

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals